

Supplementary Table 1. Trend Analysis for the Type of SCS Prescribed before a Biologic Prescription within the First Year of Newly Diagnosed CD (Step-up Group)

Trend analysis period	Initial SCS prescription before a biologic prescription				
	Prednisolone		Budesonide		Budesonide: prednisolone ratio
	No. (%)	95% CI	No. (%)	95% CI	
2010–2011 (n = 5)	5 (100.0)	47.8–100.0	0	0.0–52.2	0.0
2012–2013 (n = 4)	4 (100.0)	39.8–100.0	0	0.0–60.2	0.0
2014–2015 (n = 14)	14 (100.0)	76.8–100.0	0	0.0–23.2	0.0
2016–2017 (n = 23)	13 (56.5)	34.5–76.8	10 (43.5)	23.2–65.5	0.8
2018–2019 (n = 70)	31 (44.3)	32.4–56.7	39 (55.7)	43.3–67.6	1.3
2020 (n = 49)	19 (38.8)	25.2–53.8	30 (61.2)	46.2–74.8	1.6
Total (n = 165)	86 (52.1)	44.2–59.9	79 (47.9)	40.1–55.8	0.9

SCS, systemic corticosteroid; CD, Crohn's disease; CI, confidence interval.